Thyroid Replacement (T4) Drug-Drug Interaction Table

Why T4 Interactions Matter More Than Most Drug Classes

Levothyroxine is the most prescribed medication in the United States, with over 100 million dispensed prescriptions annually according to ClinCalc/FDA data. Its narrow therapeutic index means that even a 20 to 25% change in bioavailability can push a patient from euthyroid status into clinical hypothyroidism or subclinical hyperthyroidism [1].

The Clinical Stakes of Small Shifts

A 2014 analysis published in Thyroid found that 40 to 48% of patients on levothyroxine had TSH values outside the target range at least once during follow-up, and drug-drug interactions were among the top three identifiable causes [2]. The American Thyroid Association (ATA) 2014 guidelines specifically recommend documenting all concomitant medications at each dose titration visit [3].

Four Interaction Mechanisms

T4 interactions cluster into four pharmacologic categories: (1) reduced GI absorption, (2) increased hepatic clearance via enzyme induction, (3) altered serum protein binding, and (4) changes in peripheral deiodinase activity. Each mechanism produces a distinct pattern in thyroid function tests, and the clinical response (dose adjustment, timing separation, or increased monitoring) differs accordingly.

GI Absorption Interactions: The Largest Category

Oral levothyroxine requires an acidic gastric pH for dissolution and is absorbed primarily in the jejunum and upper ileum. Any agent that raises gastric pH, chelates T4 with polyvalent cations, or forms an insoluble complex will reduce fractional absorption [4].

Polyvalent Cation Chelators

Calcium carbonate, ferrous sulfate, aluminum hydroxide, and sucralfate each bind T4 in the GI lumen. A crossover study in 20 hypothyroid patients demonstrated that simultaneous calcium carbonate (1,200 mg) reduced levothyroxine AUC by 25% (P < 0.01) [5]. The FDA-approved labeling recommends separating calcium and iron from levothyroxine by at least 4 hours [6].

| Interacting Agent | Mechanism | Absorption Reduction | Minimum Separation | |---|---|---|---| | Calcium carbonate | Cation chelation | 20 to 25% | 4 hours | | Ferrous sulfate | Cation chelation | ~30% | 4 hours | | Aluminum hydroxide | Cation chelation | Variable | 4 hours | | Sucralfate | Surface adsorption | Up to 30% | 4 hours | | Sevelamer | Phosphate-binder binding | ~40% | 4 hours | | Cholestyramine | Bile acid resin binding | ~25% | 4 to 6 hours | | Colesevelam | Bile acid resin binding | ~15% | 4 hours |

Sevelamer deserves special attention. A study in 67 hemodialysis patients showed a mean TSH increase of 2.3 mIU/L within 8 weeks of starting sevelamer when the separation interval was under 2 hours [7].

Acid-Suppressing Agents

Proton pump inhibitors (PPIs) and H2-receptor antagonists reduce T4 dissolution by raising gastric pH above 4.0. A retrospective cohort of 1,500 patients on concurrent omeprazole and levothyroxine required a mean dose increase of 37% to maintain target TSH [8]. Lansoprazole, esomeprazole, and pantoprazole carry the same class effect. The clinical response takes 4 to 8 weeks to manifest in TSH values, because T4 has a 6 to 7 day half-life.

Short-course H2-blockers (ranitidine, famotidine) produce a smaller effect but still warrant TSH recheck at 6 weeks if used daily for longer than 14 days [9].

Practical Separation Protocol

For patients on multiple absorption-blocking agents, the simplest protocol is to take levothyroxine on an empty stomach 60 minutes before the first food, supplement, or interacting medication of the day. Bedtime dosing (3+ hours after the last meal) is an evidence-supported alternative that a randomized crossover trial showed produced equivalent TSH control in 90 patients [10].

Hepatic Enzyme Inducers: Accelerated T4 Clearance

Drugs that upregulate CYP3A4, CYP2C8, or UDP-glucuronosyltransferase (UGT) increase the hepatic clearance of both T4 and T3. The result is a falling free T4 and rising TSH, usually detectable within 2 to 4 weeks of starting the inducer.

Key Inducers

| Inducer | Enzyme Pathway | Expected TSH Rise | Dose Increase Often Needed | |---|---|---|---| | Phenytoin | CYP3A4/UGT | 2 to 5 mIU/L | 25 to 50% | | Carbamazepine | CYP3A4/UGT | 2 to 5 mIU/L | 25 to 50% | | Phenobarbital | CYP2C/UGT | 1.5 to 4 mIU/L | 20 to 40% | | Rifampin | CYP3A4/2C | 3 to 8 mIU/L | 30 to 60% | | Sertraline | Mild UGT induction | 0.5 to 2 mIU/L | 0 to 25% |

Rifampin is the most potent inducer. A pharmacokinetic study showed that rifampin 600 mg daily reduced the half-life of T4 from 6.7 to 3.8 days in euthyroid volunteers [11]. This effect persists for 2 to 3 weeks after rifampin discontinuation due to the slow offset of enzyme induction.

Antiepileptic Monitoring

Phenytoin carries a secondary mechanism: it displaces T4 from thyroxine-binding globulin (TBG), which transiently raises free T4 before the increased clearance dominates. Initial labs drawn within the first 5 to 7 days of adding phenytoin may therefore show a paradoxically normal or high free T4 with a low total T4, which can be misinterpreted. The ATA recommends waiting at least 4 to 6 weeks and using TSH as the primary guide rather than free T4 alone in this specific scenario [3].

Tyrosine Kinase Inhibitors

Imatinib, sunitinib, and sorafenib increase levothyroxine requirements in athyreotic patients by 50 to 100%, likely through UGT induction and increased type 3 deiodinase expression [12]. A 2017 retrospective study of 68 thyroid cancer patients on sorafenib found that 78% required a levothyroxine dose increase within 8 weeks, with a median increase of 63% [13]. Patients with an intact thyroid gland may compensate partially through increased endogenous T4 production.

Protein-Binding Displacement Interactions

Approximately 99.97% of circulating T4 is protein-bound, primarily to TBG, transthyretin, and albumin. Drugs that alter binding protein concentrations or displace T4 from binding sites change the total T4/free T4 ratio and may alter TSH.

Estrogen and TBG Elevation

Oral estrogens (conjugated equine estrogens, ethinyl estradiol in OCs) increase hepatic TBG synthesis, raising total T4 while lowering the free fraction. In hypothyroid patients on fixed-dose levothyroxine, this manifests as a rising TSH. A prospective study in 21 women starting oral HRT found a mean TSH increase of 1.8 mIU/L at 12 weeks, and 60% required a levothyroxine dose increase [14]. Transdermal estradiol does not significantly alter TBG levels and is the preferred route in this population [15].

Drugs That Lower TBG or Displace T4

Androgens, anabolic steroids, and high-dose glucocorticoids suppress TBG synthesis, raising free T4 transiently and potentially lowering TSH. High-dose salicylates (> 2 g/day) and furosemide (> 80 mg IV bolus) directly displace T4 from binding proteins. These effects are generally transient, but the FDA labeling for levothyroxine lists both as interactions requiring monitoring [6].

| Binding Interaction | Direction of Free T4 | TSH Effect | Action | |---|---|---|---| | Oral estrogen (TBG ↑) | ↓ initially | ↑ | Increase T4 dose 25 to 50 mcg; recheck 6 to 8 wk | | Androgens (TBG ↓) | ↑ transiently | ↓ | Monitor; may reduce T4 dose | | High-dose salicylates | ↑ transiently | ↓ short-term | Usually no dose change; monitor | | Furosemide IV bolus | ↑ transiently | Minimal | No dose change; avoid drawing TSH same day |

Drugs That Alter Peripheral T4-to-T3 Conversion

Type 1 and type 2 deiodinases convert T4 to the active hormone T3 in peripheral tissues. Several drugs inhibit this conversion, raising T4 and reverse T3 while lowering T3.

Amiodarone

Amiodarone is the highest-impact drug in this category. Each 200 mg tablet contains 75 mg of organic iodine, which inhibits type 1 deiodinase and can trigger either amiodarone-induced hypothyroidism (AIH) or amiodarone-induced thyrotoxicosis (AIT). The Wolff-Chaikoff effect drives AIH in patients with underlying autoimmune thyroid disease. A meta-analysis of 12 studies (N = 1,465) found AIH incidence of 6% in iodine-sufficient populations and up to 13% in iodine-replete populations with Hashimoto thyroiditis [16].

In patients already on levothyroxine, adding amiodarone typically raises TSH by 2 to 4 mIU/L within 3 months. TSH should be checked at baseline, 3 months, and every 6 months thereafter for the duration of amiodarone therapy and for 12 months after discontinuation, given amiodarone's 40 to 55 day half-life.

Beta-Blockers and Glucocorticoids

Propranolol at doses above 160 mg/day inhibits type 1 deiodinase, measurably reducing T3 by 15 to 20% [17]. This is clinically useful in thyroid storm but can mask recovery in monitored hypothyroid patients. Dexamethasone at doses above 2 mg/day produces a similar effect on peripheral conversion, and the Endocrine Society guidelines note this as a factor when interpreting thyroid function tests in hospitalized patients [18].

Warfarin and Oral Anticoagulant Interactions

Thyroid hormones increase catabolism of vitamin K-dependent clotting factors. As levothyroxine dose increases or a previously undertreated patient achieves euthyroid status, warfarin sensitivity rises. The INR effect may not appear for 1 to 2 weeks after a levothyroxine dose change because of the slow equilibration of clotting factor pools.

Monitoring Protocol

The ATA and the American College of Chest Physicians both recommend rechecking INR 1 to 2 weeks after any levothyroxine dose adjustment in patients on warfarin [3]. A retrospective study of 234 patients on concurrent therapy found that 31% required warfarin dose reduction within 6 weeks of achieving target TSH after dose optimization [19].

Direct oral anticoagulants (DOACs) have fewer pharmacokinetic interactions with levothyroxine, though post-marketing surveillance data remains limited. Apixaban and rivarelbaan clearance does not appear to be meaningfully altered by thyroid status changes in the available pharmacokinetic analyses [20].

GLP-1 Receptor Agonists and Metformin

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) slow gastric emptying, which can delay levothyroxine absorption. Semaglutide prescribing information notes a reduction in levothyroxine Cmax of 33% and AUC of 13% when co-administered orally, though the clinical significance in patients on stable doses remains under study [21].

Metformin has been shown to lower TSH by 0.4 to 0.8 mIU/L in hypothyroid patients on levothyroxine in a meta-analysis of 7 studies (N = 904), possibly through a TSH-independent effect on hypothalamic-pituitary signaling [22]. The mechanism is not fully characterized, but clinicians should be aware that metformin initiation may produce a TSH decrease that does not represent overreplacement.

Complete DDI Quick-Reference Table

| Drug/Class | Mechanism | Clinical Effect | Management | |---|---|---|---| | Calcium, iron, aluminum | Cation chelation | ↑ TSH | Separate by 4 h | | PPIs (omeprazole, etc.) | ↓ gastric acid | ↑ TSH | May need 25 to 50% higher T4 dose | | Cholestyramine, colesevelam | Bile acid resin binding | ↑ TSH | Separate by 4 to 6 h | | Sevelamer | Phosphate-binder binding | ↑ TSH | Separate by 4 h; recheck TSH 6 wk | | Sucralfate | Surface adsorption | ↑ TSH | Separate by 4 h | | Phenytoin | CYP induction + TBG displacement | ↑ TSH after 2 to 4 wk | Increase T4 dose 25 to 50%; use TSH not fT4 | | Carbamazepine | CYP/UGT induction | ↑ TSH | Increase T4 dose; recheck 6 wk | | Rifampin | CYP3A4/2C induction | ↑ TSH | Increase T4 dose 30 to 60% | | Imatinib, sunitinib, sorafenib | UGT induction + type 3 deiodinase | ↑ TSH (athyreotic patients) | Increase T4 dose 50 to 100% | | Oral estrogens | ↑ TBG synthesis | ↑ TSH | Increase T4 dose; consider transdermal route | | Androgens | ↓ TBG synthesis | ↓ TSH (transient) | Monitor; may reduce T4 | | Amiodarone | Deiodinase inhibition + iodine load | ↑ TSH (AIH) or ↓ TSH (AIT) | TSH at baseline, 3 mo, q6 mo | | Propranolol (> 160 mg/d) | Type 1 deiodinase inhibition | ↓ T3 | Monitor T3 if clinically relevant | | Warfarin | ↑ clotting factor catabolism | ↑ INR as euthyroid achieved | Recheck INR 1 to 2 wk post-T4 change | | Semaglutide (oral) | Delayed gastric emptying | ↓ T4 Cmax | Monitor TSH after GLP-1 initiation | | Metformin | Uncertain (hypothalamic-pituitary) | ↓ TSH 0.4 to 0.8 mIU/L | Do not reduce T4 dose reflexively | | Sertraline | Mild UGT induction | ↑ TSH (small) | Recheck TSH at 8 wk |

Monitoring Cadence After Adding or Removing an Interacting Drug

For any new interacting drug, recheck TSH 6 to 8 weeks after initiation at steady state. If the interacting drug is discontinued, recheck TSH again at 6 to 8 weeks, because the prior levothyroxine dose adjustment may now cause overreplacement. Patients on warfarin require INR checks at 1 to 2 week intervals until stable, independent of TSH timing. For amiodarone, extend monitoring to every 6 months during therapy and 12 months after cessation, per ATA guidance [3].